Edition: United Kingdom  
One News Page
“Probably the fastest-access news portal in the world”
Actelion News  |<  Page 1  >> 
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

Actelion spin-off Idorsia up 30% on market debut

Pharma group valued at SFr1.5bn despite no significant revenues expected for 3 years
FT.com

EU approves Johnson & Johnson's $30bn purchase of Actelion

eu approves johnson & johnson's $30bn purchase of actelion
The European Commission today approved the planned sale of Swiss pharmaceuticals firm Actelion to Johnson & Johnson (J&J), subject to conditions. EU regulators qualified the sale of Europe's biggest..
City A.M.

Videos for actelion

News video: J&J CEO Gorsky on M&A, Health Care, Tax Reform

J&J CEO Gorsky on M&A, Health Care, Tax Reform 15:01

Jun.26 -- Alex Gorsky, chairman and chief executive officer at Johnson & Johnson, discusses the company’s purchase of Actelion, the state of health care in the United States, and what tax reform..
Source: Bloomberg Politics -

 

J&J garners EU approval for $30bn Actelion deal


FT.com

EU approves J&J purchase of Actelion subject to conditions

BRUSSELS (Reuters) - EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion Pharmaceutical subject to conditions intended to ensure clinical development of insomnia..
Reuters

Actelion antibiotic misses mark on one study, hits it on another

ZURICH (Reuters) - Swiss biotechnology company Actelion on Thursday presented mixed trial results for its antibiotic hopeful cadazolid, saying it met the main goal of one late-stage study but failed to..
Reuters

J&J's quarterly sales rise 1.6 percent

(Reuters) - Johnson & Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday a 1.6 percent rise in first-quarter sales.
Reuters

EMA gives green light to Actelion's Uptravi after safety review

ZURICH (Reuters) - The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion's Uptravi, saying a review after five patient deaths in France did not suggest an..
Reuters

J&J declares Actelion tender offer a success, sees closing in second quarter

ZURICH (Reuters) - Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after..
Reuters

It's official: Deal volumes hit highest level since the financial crisis

it's official: deal volumes hit highest level since the financial crisis
Global M&A activity so far this year is at its highest level since the financial crisis, expert analysis has revealed. Some $705bn of deals have been announced since the start of 2017, the first..
City A.M.

Actelion, being bought by J&J, says full year profit rose 26 percent

ZURICH (Reuters) - Swiss drugmaker Actelion said on Tuesday that its full year 2016 net income rose 26 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial..
Reuters

MY INVESTMENTS: Samantha Gleave on Actelion and Opap

my investments: samantha gleave on actelion and opap
Actelion Pharmaceuticals had a very attractive pipeline of new drugs in development. But OPAP, a Greek lottery and sports betting operator, was hit hard by the political crisis in the country.
MailOnline

EMA panel recommends that use of Actelion's Uptravi may continue

ZURICH (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used in line with current prescription information amid a probe..
Reuters

BRIEF-J&J says upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee

* J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing Source text - http://bit.ly/2jWFeAh Further company coverage:
Reuters

Actelion, Syngenta takeovers set to shake up Swiss SMI index

ZURICH (Reuters) - The looming foreign takeovers of biotech group Actelion and agrichemicals firm Syngenta look set to trigger the biggest shake-up in the Swiss blue-chip SMI index in years just as..
Reuters

J&J digs deep to claim $30bn Actelion prize

Biggest deal in group’s 130-year history is unusual in timing and concessions made
FT.com

J&J boss’s long quest ends with Actelion deal

Questions asked about price paid for Swiss group and spin-off of promising new drugs
FT.com

You Might Like


 |<  Page 1  >> 
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+